These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 26990290)

  • 21. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
    Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
    DeAngelo DJ; Stone RM; Heaney ML; Nimer SD; Paquette RL; Klisovic RB; Caligiuri MA; Cooper MR; Lecerf JM; Karol MD; Sheng S; Holford N; Curtin PT; Druker BJ; Heinrich MC
    Blood; 2006 Dec; 108(12):3674-81. PubMed ID: 16902153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.
    Morales ML; Arenas A; Ortiz-Ruiz A; Leivas A; Rapado I; Rodríguez-García A; Castro N; Zagorac I; Quintela-Fandino M; Gómez-López G; Gallardo M; Ayala R; Linares M; Martínez-López J
    Sci Rep; 2019 Dec; 9(1):18630. PubMed ID: 31819100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
    Tolcher AW; Kurzrock R; Valero V; Gonzalez R; Heist RS; Tan AR; Means-Powell J; Werner TL; Becerra C; Wang C; Leonowens C; Kalyana-Sundaram S; Kleha JF; Gauvin J; D'Amelio AM; Ellis C; Ibrahim N; Yan L
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):673-683. PubMed ID: 32062691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.
    Hyrenius-Wittsten A; Sturesson H; Bidgoli M; Jonson T; Ehinger M; Lilljebjörn H; Scheding S; Andersson AK
    Genes Chromosomes Cancer; 2016 Nov; 55(11):847-54. PubMed ID: 27240832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
    Badar T; Cortes JE; Ravandi F; O'Brien S; Verstovsek S; Garcia-Manero G; Kantarjian H; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):433-438.e2. PubMed ID: 25795639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved survival with MEK inhibition in BRAF-mutated melanoma.
    Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
    N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
    Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
    Kurzrock R; Ball DW; Zahurak ML; Nelkin BD; Subbiah V; Ahmed S; O'Connor A; Karunsena E; Parkinson RM; Bishop JA; Ha Y; Sharma R; Gocke CD; Zinner R; Rudek MA; Sherman SI; Azad NS
    Clin Cancer Res; 2019 Sep; 25(18):5475-5484. PubMed ID: 31186313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
    Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
    Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trametinib Sensitivity is Defined by a Myeloid Differentiation Profile in Acute Myeloid Leukemia.
    Quesnel-Vallières M; Schultz DC; Orlenko A; Lo Y; Moore J; Ritchie M; Roth D; Carroll M; Barash Y; Lynch KW; Cherry S
    Drugs R D; 2024 Sep; 24(3):489-499. PubMed ID: 39316279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.
    Decroocq J; Birsen R; Montersino C; Chaskar P; Mano J; Poulain L; Friedrich C; Alary AS; Guermouche H; Sahal A; Fouquet G; Gotanègre M; Simonetta F; Mouche S; Gestraud P; Lescure A; Del Nery E; Bosc C; Grenier A; Mazed F; Mondesir J; Chapuis N; Ho L; Boughalem A; Lelorc'h M; Gobeaux C; Fontenay M; Recher C; Vey N; Guillé A; Birnbaum D; Hermine O; Radford-Weiss I; Tsantoulis P; Collette Y; Castellano R; Sarry JE; Pasmant E; Bouscary D; Kosmider O; Tamburini J
    Leukemia; 2022 May; 36(5):1237-1252. PubMed ID: 35354920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
    Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD
    Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
    Braun T; Fenaux P
    Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.
    Uppaluri R; Winkler AE; Lin T; Law JH; Haughey BH; Nussenbaum B; Paniello RC; Rich JT; Diaz JA; Michel LP; Wildes T; Dunn GP; Zolkind P; Kallogjeri D; Piccirillo JF; Dehdashti F; Siegel BA; Chernock RD; Lewis JS; Adkins DR
    Clin Cancer Res; 2017 May; 23(9):2186-2194. PubMed ID: 28151720
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of
    Mustafa Ali MK; Williams MT; Corley EM; AlKaabba F; Niyongere S
    Leuk Lymphoma; 2023 May; 64(5):962-971. PubMed ID: 37042657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.